Classical Hodgkin lymphoma (cHL) is an aggressive disease that develops in the lymphatic system, part of the immune system. It can develop at any age but occurs most frequently in two age groups: ...
The treatment of newly diagnosed multiple myeloma (NDMM) has evolved significantly in recent years with the introduction of quadruplet regimens, which typically combine an anti-CD38 monoclonal ...
Below are summaries of recent publications involving ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) researchers and trial data. The publications cover breast cancer, lymphoma, precision oncology, and ...
The ECOG-ACRIN Fall 2026 Group Meeting is quickly approaching, but there is still time to register! Join us in person October ...
EAQ241CD – Addressing Financial Hardship in AYA Cancer Survivors: Efficacy and Implementation of a Multilevel Intervention (LIFT UP) in Community-Based Oncology Practices Individuals diagnosed with ...
Below are summaries of recently published analyses from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). Click on the shortened citations to access the publications.
Melanoma is one of the most common cancers in the United States, with diagnoses increasing more rapidly than most other common cancers despite public awareness campaigns recommending sunscreens and ...
Below, we feature 10 cancer research advances during 2025 that captured attention across the scientific and patient advocacy communities. Eight of the discoveries are from cancer clinical trials ...
Identifying the optimal sequence of therapies for patients with progressive radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) is a question commonly encountered in practice, posing a ...
Now Enrolling: EA8231 Study for Patients With Bladder Cancer That Has Progressed Following Treatment
A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs. Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer Bladder cancer (urothelial carcinoma) ...
For adolescent and young adult (AYA) cancer survivors, the demands of their illness may compound normal developmental challenges and adversely affect physical, emotional, and social health. Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results